UCB SA (UCBJF)

Market Cap	53.75B
Revenue (ttm)	8.04B
Net Income (ttm)	1.56B
Shares Out	n/a
EPS (ttm)	8.06
PE Ratio	34.36
Forward PE	27.06
Dividend	1.58 (0.54%)
Ex-Dividend Date	Apr 25, 2025

Volume	105
Average Volume	584
Open	292.34
Previous Close	289.65
Day's Range	292.34 - 292.34
52-Week Range	150.70 - 306.79
Beta	0.28
RSI	54.96
Earnings Date	Feb 26, 2026

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spra...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1925
• Employees: 9,378
• Stock Exchange: OTCMKTS
• Ticker Symbol: UCBJF

Financial Performance

In 2024, UCB SA's revenue was 6.15 billion, an increase of 18.72% compared to the previous year's 5.18 billion. Earnings were 1.07 billion, an increase of 210.50%.

Financial numbers in EUR